51st week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170360640 | HOUSING FOR COFFINS - A housing for keeping, transporting and entombing a corpse comprising a bottom with an outer peripheral edge and a lid ( | 2017-12-21 |
20170360641 | MASSAGE UNIT AND MASSAGE MACHINE HAVING MASSAGE UNIT - A massage unit includes a treatment member; an arm that supports the treatment member; a drive shaft that supports the arm and causes the treatment member to approach and be separated with respect to a treatment target site; a movable portion that causes the treatment member to be operable in a direction of being separated from the treatment target site when the treatment member comes into contact with the treatment target site by a force equal to or greater than predetermined strength; and biasing means for biasing the treatment member in an approaching direction. | 2017-12-21 |
20170360642 | Spine Alignment And Decompression Systems - A system can include a base configured to support a lower half of a human body. The system can also include a headrest elevated relative to the base, wherein the headrest is disposed adjacent to a proximal end of the base, where the headrest is configured to support a head of the human body. The system can further include a back platform having a first end and a second end, where the first end is coupled to the base, where the second end is disposed adjacent to the headrest, and where the back platform has a curvature, where the back platform is configured to support a torso of the human body. The system can also include a vibrating mechanism in communication with the back platform, where vibrations generated by the vibrating mechanism translate to the back platform. | 2017-12-21 |
20170360643 | METHOD AND APPARATUS FOR RELIEVING PHYSICAL DISCOMFORT - A pressure applicating assembly for treatment of menstrual cramps and other discomfort; the apparatus comprising a pressure applicator apparatus and a flexible strap. The pressure applicator apparatus comprises a plurality of styluses arranged in both a direction parallel to the strap and a direction perpendicular to the strap. The pressure applicator apparatus is secured to a patient using the strap in a manner to apply pressure to a tender location on an interior region of a patient's calf. The applied pressure can be employed to relieve the patient of menstrual discomfort by identifying the tender spot by applying light pressure to a menstrual discomfort controlling pressure region. The identified tender spots are considered the menstrual discomfort controlling pressure points. The plurality of styluses applies a distributed pressure to the region to ensure the tender spots are sufficiently addressed, thus relieving the patient of the discomfort. | 2017-12-21 |
20170360644 | ANKLE-LESS WALKING ASSISTANT APPARATUS AND METHOD FOR CONTROLLING THE SAME - An ankle-less walking assistant apparatus includes: a body supporting the back of a wearer; left and right hip joint-drivers extending from both sides of the body; left and right thigh links having first ends connected to the left and right hip joint-drivers, respectively; left and right knee-drivers connected to second ends of the left and right thigh links, respectively; left and right calf links having first ends connected to the left and right knee-drivers, respectively; and ground-contact feet fixed to second ends of the left and right calf links, respectively. | 2017-12-21 |
20170360645 | MOVEMENT ASSISTANCE DEVICE - A movement assistance device is provided with thigh frames, lower leg frames, and knee joint mechanisms which are disposed on the outer side and the inner side, respectively, of each knee of a person to be assisted. Each of the thigh frames has a first main frame, which extends in the longitudinal direction of a thigh from a base disposed on one side of the hip of the person to be assisted to the outer knee joint mechanism, a second main frame, which obliquely extends on the front side of the thigh from the base to the inner knee joint mechanism, and a body support member, which is extended between the two main frames on the rear surface side of the thigh. | 2017-12-21 |
20170360646 | EXOSKELETON AND METHOD OF OPERATION THEREOF - In an embodiment, an exoskeleton that can be applied to a limb of a wearer (P) includes a first member ( | 2017-12-21 |
20170360647 | DEVICE AND METHOD FOR INSTILLING INTRINSIC MOTIVATION REGARDING EYE CONTACT IN CHILDREN AFFECTED BY EYE CONTACT DISORDERS - This describes a treatment method for autism/ASD intended to encourage greater eye contact by affected children. The treatment method incorporates an artificial demonstration of the phenomenon of eye contact, and that method is described herein along with the principles of action of the treatment and the necessary procedure to perform it. Also described are two embodiments of the physical portion of the invention that can be used for the demonstration: first, an item in the form of a cuboid with animatronic eyes affixed to one side that most purely reflects the principles behind the treatment, and second, another in the form of a stuffed toy that is perhaps more practical. | 2017-12-21 |
20170360648 | AIR-SUCTION, HEATING AND VIBRATION PHYSIOTHERAPEUTIC BAR - An air-suction, heating and vibration physiotherapeutic bar, comprises a surface cover, a bottom cover, a DC plug and at least one key. An air pump, a battery, an electronic valve, a PCBA, a motor and a massage device are installed in a space encircled by the bottom cover and the surface cover; the DC plug is electrically connected with the PCBA by a lead; one end of the bottom cover is provided with an air-suction hole; a silica gel suction nozzle of a through hole is sleeved at the air-suction hole; the electronic valve is connected with the air pump by a three-way air tube; the other end of the three-way air tube is connected with the air-suction hole. The air-suction, heating and vibration physiotherapeutic bar of the present invention has simple structure, has physiotherapeutic functions of vacuum air-suction flapping, heating and vibration massage. | 2017-12-21 |
20170360649 | POST-SURGICAL OBSTRUCTION TREATMENT RECOVERY AND REHABILITATION THERAPY - Medical pressure therapy can be used on a patient having undergone treatment to reopen an arterial obstruction, such as a stenosis or occlusion. The medical pressure therapy can establish and maintain persistently good distal runoff. The can help ensure the patency of the region having undergone the treatment procedure. In some examples, the technique involves enclosing at least a portion of a limb of a patient on which an obstruction treatment procedure has been performed in an enclosure such that the portion of the limb is sealed from external conditions. The technique further involves alternately applying a negative pressure within the enclosure and releasing the negative pressure from within the enclosure, thereby increasing a volume and velocity of blood flowing past a region of the blood vessel previously-obstructed and thereby increasing distal runoff. | 2017-12-21 |
20170360650 | Foot Massaging Assembly - A foot massaging assembly for massaging a user's feet includes a stand that may be positioned on a support surface. The stand may be vertically oriented on the support surface. A massage unit is slidably coupled to the stand. A bottom side corresponding to each of a user's feet may be rolled on the massage unit. Thus, the massage unit may massage the user's feet. The massage unit is selectively positioned at a selected point along the stand. | 2017-12-21 |
20170360651 | MASSAGE UNIT AND MASSAGE MACHINE - It is a primary object of the present invention to provide a massage unit and a massage machine which can increase a protruding amount of a massage ball. A massage unit | 2017-12-21 |
20170360652 | PORTABLE THERAPEUTIC DEVICE AND ASSOCIATED USE THEREOF - A portable therapeutic device includes a portable body having a recessed central region and a raised outer peripheral edge surrounding the recessed central region and directly engaged with the recessed central region, a plurality of massage balls seated at the recessed central region and spaced inside a perimeter of the raised outer peripheral edge, a thermal-conductive element channeled inside the outer peripheral edge and spaced from the recessed central region, and a power source communicatively coupled to the massage balls and the thermal-conductive element. | 2017-12-21 |
20170360654 | TREATMENT FOR LARGE VOLUME BIOLOGICAL TARGETS WITH A HIGH PRESSURE SHOCKWAVE INSTRUMENT - The present invention relates to a device, system and a method for high pressure shockwave treatment of biological tissue having a large treatment zone and in particular to such a device, system and method in which a large biological treatment area in treated in a non-drug, non-surgical treatment protocol utilizing ballistic shockwave generating device. | 2017-12-21 |
20170360655 | Enhanced Guided Active Compression Decompression Cardiopulmonary Resuscitation Systems and Methods - Systems and methods for applying enhanced guided active compression decompression cardiopulmonary resuscitation are provided. Exemplary systems include a load cell, a handle, an adhesive pad. The handle and the adhesive pad are configured for magnetic coupling. | 2017-12-21 |
20170360656 | PORT, AND MEDICAL LIQUID BAG - An object is to provide a port that is capable of securely preventing pulling-out of a sealing plug from a port body. Provided is a port including: a sealing plug through which a hollow needle can be pierced; a port body having a hollow structure with the sealing plug disposed therein; and a pulling-out preventing member to be attached to the port body. The port body includes: a part to be sealed that has a tubular shape with a first end and a second end opposite to the first end, and is configured so that the sealing plug is sealingly inserted into the part to be sealed; a connection part that has a tubular shape, is continuous with the first end of the part to be sealed, and has an outer periphery connected to the bag body to be filled with a medical liquid; and a part to be fitted that is formed in any one of an inner peripheral surface of the part to be sealed, an outer peripheral surface of the part to be sealed, and the second end of the part to be sealed. The pulling-out preventing member includes: a body part that has a first surface directed toward the first end of the part to be sealed within the part to be sealed; a restriction part that is formed on the first surface of the body part and restricts movement of the sealing plug toward the second end of the part to be sealed; and a fitting part that comes into fitting engagement with the part to be fitted of the port body. | 2017-12-21 |
20170360657 | COMPOSITION COMPRISING POLYMER PARTICLES, A HYDROCARBON-BASED OIL AND A HYDROCARBON-BASED BLOCK COPOLYMER, AND PROCESS USING THE SAME - The present invention relates to a composition comprising particles of at least one polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C | 2017-12-21 |
20170360658 | ANHYDROUS COMPOSITION IN AEROSOL FORM COMPRISING AN ANTIPERSPIRANT ACTIVE AGENT AND A WATER-INSOLUBLE FILM-FORMING BLOCK ETHYLENIC POLYMER AND A PHENYL SILICONE - The present invention relates to an anhydrous composition in aerosol form comprising, in particular in a physiologically acceptable medium:
| 2017-12-21 |
20170360659 | MULTIFUNCTIONAL BASE EMULSION - Multi-functional base emulsions that can be used to form a variety of cosmetic compositions are disclosed. In one aspect, a cosmetic emulsion can include a water phase including about 10% to about 67.5% water by total weight of the cosmetic emulsion. The cosmetic emulsion can also include an oil phase that includes (a) stearalkonium hectorite, and (b) a silicone alkyl polyether selected from the group consisting of: PEG/PPG-18/18 dimethicone, PEG/PPG-20/15 dimethicone, and Lauryl PEG/PPG-18/18 dimethicone. | 2017-12-21 |
20170360660 | MICROCAPSULES - The present invention relates to microcapsules comprising a capsule core and a capsule shell wherein the capsule shell comprises a core surrounding layer of a polyvinyl alcohol and an adjacent layer of a polyoxazoline, a process of their production and their use. | 2017-12-21 |
20170360661 | EMULSIONS STABILISED BY AMPHIPHILIC COMPOSITE PARTICLES - The present invention relates to an emulsion not containing any emulsifying surfactant, in particular to an oil-in-water emulsion not containing any emulsifying surfactant, characterized in that it comprises, especially in a physiologically acceptable medium, at least composite particles comprising a core comprising at least organic or inorganic particles A; said core being covered at the surface, continuously or discontinuously, with an envelope comprising at least organic or inorganic particles B; said particles A and B having different polarities. | 2017-12-21 |
20170360662 | COSMETIC COMPOSITION CAPABLE OF SIMULTANEOUSLY COLORING HAIR AND RELAXING CURLS - A one step hair color and relaxer system comprising: an alkalizing agent in the range between about 0.1% to about 8%, based upon the total concentration of the hair color and relaxer system; a hair dye; and an oxidizing agent in the range between about 0.1% to about 6%, based upon the total concentration of the hair color and relaxer system; wherein the pH of the hair color and relaxer system is in the range between about 9 to about 14. | 2017-12-21 |
20170360663 | STABLE COLOR-PROTECTING HAIR TREATMENT AGENT COMPRISING LANTHANIDE SALT - A hair treatment agent for reducing and/or preventing the bleeding out and/or fading of artificially produced hair colors is provided herein. The hair treatment agent has a pH value in the range of from about 4 to about 5. The hair treatment agent includes, relative to the total amount of the hair treatment agent, from about 0.01 to about 10% by weight of a lanthanum and/or lanthanide salt, at least one anionic surfactant selected from the group of alkyl (ether) sulfates, sulfosuccinates, ether carboxylic acids, N-acylamino acids having 8 to 24 C atoms in the acyl group, (acyl) isethionates having 8 to 24 C atoms in the acyl group, and mixtures of these surfactants, and from about 0.01 to about 10% by weight of an organic acid selected from the group of maleic acid, lactic acid, acetic acid, propanoic acid, amino acids, and mixtures thereof. | 2017-12-21 |
20170360664 | PERSONAL CARE COMPOSITIONS - Described herein, are aqueous soluble tin phosphate complexes formed from a mixture comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., sodium tripolyphosphate (Na | 2017-12-21 |
20170360665 | NOVEL 1-PHENYLMONO- OR -POLYHYDROXYPROPANE COMPOUNDS, COMPOSITIONS AND COSMETIC USES THEREOF - The present invention relates to novel compounds of formula (I) | 2017-12-21 |
20170360666 | SOLUBILIZING AGENTS FOR UV FILTERS IN COSMETIC FORMULATIONS - The present invention relates to the use of the compounds (A) corresponding to formula | 2017-12-21 |
20170360667 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES - The present application relates to new compounds in the family of N-acylamino-amides having formula (I), compositions, in particular cosmetic compositions comprising them, and their use to treat the signs of aging of skin of the body or face, whether chronobiological or photo-induced, and in particular aging generated by reduced skin elasticity. | 2017-12-21 |
20170360668 | USE OF ESTER DERIVATIVE OF TRYPTOPHAN AS DEODORANT AND/OR PERFUME AGENT - This invention relates to the use of at least one following compound having formula (I),as ell as the salts thereof,the optical and geometric isomers thereof, and the solvates thereof, as deodorant agent for treating body odor, preferably underarm odor: | 2017-12-21 |
20170360669 | NON- MUTAGENIC PHOTO CHROMIC DYE - A method of solubilizing a composition, such as an organic manufactured photochromic dye that is free of carcinogens, non-mutagenic, non-toxic to human skin in any concentration, and suitable for application to, and absorbable by, human skin. The photochromic dye is suitable to be applied directly to human skin, and which dye is configured to indicate exposure to UV rays. The composition is configured to change color upon exposure to UVA, UVB and/or UVC rays. The composition can be used with other compositions, such as sunscreen, and be applied to human skin prior to application of the sunscreen, or, formulated with the sunscreen such that when the active ingredients of the sunscreen diminish, the photochromic dye will change color to generate a visual indicator of this condition. | 2017-12-21 |
20170360670 | AQUEOUS OXIDIZING COMPOSITION - The present invention relates to an aqueous oxidizing composition comprising one or more oxidizing agent, one or more sugar and/or one or more polyethylene glycol and having a pH in the range of 1 to 5. | 2017-12-21 |
20170360671 | METHOD FOR PREPARING 3,6-ANHYDRO-L-GALACTOSE, AND USE THEREOF - The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof. | 2017-12-21 |
20170360672 | SURFACTANT COMPOSITION - A surfactant composition comprising a sugar-based surfactant comprising a C8-C16 alkyl glucoside, a C8-C16 alkyl polyglucoside, or a combination of a C8-C16 alkyl glucoside and a C8-C16 alkyl polyglucoside; a C8-C18 amphodiacetate; a C8-C16 acyl sarcosinate, a C8-C16 acyl glutamate, a C8-C16 acyl glycinate, or a combination thereof; and optionally a C8-C14 acyl lactylate, wherein the composition is free of sulfated anionic surfactants. | 2017-12-21 |
20170360673 | HAIR COMPOSITION - Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth, wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine. | 2017-12-21 |
20170360674 | HAIR TREATMENT AGENT CONTAINING AT LEAST ONE ACID PROTEIN AND AT LEAST ONE SALT - A cosmetic agent for treating keratin fibers is provided herein. The cosmetic agent includes, in a cosmetically acceptable carrier, in relation to the total weight of the cosmetic agent, from about 0.001 to about 10 wt. % of at least one protein which has a content of glutamic acid and/or aspartic acid of from about 10 to about 60%, in relation to the total content of all amino acids of the protein. The cosmetic agent further includes, in a cosmetically acceptable carrier, in relation to the total weight of the cosmetic agent, from about 0.01 to about 10 wt. % of at least one salt which includes at least one divalent cation, and/or of at least one salt which includes at least one trivalent cation. | 2017-12-21 |
20170360675 | Cosmetic Composition and Methods of Use Thereof - The present invention relates generally to the field of cosmetics. More particularly, it concerns compositions that can be used to exfoliate, moisturize, or prepare skin for moisturization. In another aspect, the composition can be used as a cleanser to remove dirt, oil, grease, tars, etc. from surfaces. | 2017-12-21 |
20170360676 | POLYSACCHARIDE DELIVERY PARTICLE - Disclosed are: (a) controlled release matrix particles containing 10-70 wt. % of a hydrophobic active ingredient, 21-72 wt. % of a polysaccharide, 3.80-12 wt. % of a crosslinking agent, 1.00-6 wt. % of a catalyst and 0.10-5 wt. % of a silica flow aid; (b) controlled release core/shell particles containing 10-70 wt. % of a hydrophobic active ingredient, 1.0-3.2 wt. % of an epoxidized oil, 21-64 wt. % of a polysaccharide, 7.6-23% of an amine-functionality containing material, and 0.10-5 wt. % of a silica flow aid; and (c) hybrid particles wherein the core/shell particles are contained in a matrix. Also disclosed are methods for making the particles and compositions containing the particles. | 2017-12-21 |
20170360677 | COSMETIC PROCESS FOR ATTENUATING WRINKLES - The invention relates to a cosmetic process for caring for the skin, more particularly facial skin, in particular wrinkled skin, comprising the topical application to the skin of a cosmetic composition comprising a grafted polysaccharide polymer (I) and exposure of the treated skin to light radiation, polymer (I) being of formula: | 2017-12-21 |
20170360678 | COSMETIC METHOD FOR CONTROLLING ODORS - The invention relates to a cosmetic method for treating human body odors. Said method includes: | 2017-12-21 |
20170360679 | Chitosan: Aldehyde Film-Coated Fibers or Hairs, Related Methods and Compositions - The invention includes methods of forming a semi-permanent film on a fiber comprising topically applying an effective amount of a composition to the hair and exposing the hair to a temperature of about 50° C. or greater thereby forming a film on the hair. The composition comprises a chitosan, an aldehyde-bearing compound, and an organic acid. Also included are the compositions that form the film, specifically compositions that form a semi-permanent film on a fiber in the presence of heat comprising a chitosan, an aldehyde-bearing compound, and an organic acid. Other, related methods are within the scope of the invention. | 2017-12-21 |
20170360680 | CLEAR SUSPENDING PERSONAL CARE CLEANSING COMPOSITIONS - Compositions of the present invention include an anionic surfactant, a zwitterionic surfactant, a superhydrophilic amphiphilic copolymer, an organic acid; and a polymer selected from the group consisting of a non-hydrophobically modified alkali-swellable emulsion polymer and a non-crosslinked hydrophobically modified acid-swellable emulsion polymer, wherein, when the composition contains the non-hydrophobically modified alkali-swellable emulsion polymer, the non-hydrophobically modified alkali-swellable emulsion polymer is present in an amount of about 0.1% to 5% by weight, and when the composition contains the non-crosslinked hydrophobically modified acid-swellable emulsion polymer, the non-hydrophobically modified acid-swellable emulsion polymer is present in an amount of about 0.1% to 5% by weight, and wherein the composition has an NTU value of 95 or less, a yield value of about 0.1 Pascal or more and pH of from about 3 to about 6.5. | 2017-12-21 |
20170360681 | SKIN-PROTECTIVE EMULSIONS - Cosmetic oil-in-water emulsions that can provide a hydrophobic film to protect from excessive hydration are disclosed. In some aspects, a cosmetic oil-in-water emulsion can include water at a concentration of at least about 70% by total weight of the cosmetic oil-in-water emulsion, a plurality of water-in-oil emulsifiers, a base oil, an oil-in-water emulsifier, and a film-forming polymer. The base oil can have a wVTR of about 1.0 to 30 g/m | 2017-12-21 |
20170360682 | COMPOSITION COMPRISING POLYMER PARTICLES AND A MINERAL THICKENER, AND PROCESS USING THE SAME - The present invention relates to a composition comprising particles of a polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C | 2017-12-21 |
20170360683 | One Part Acrylic Nail Formulation - A pot-stable photopolymerizable composition for forming a cosmetic coating for nails comprises a mixture of a poly(alkyl(meth)acrylate powder, (meth)acrylate oligomer, (meth)acrylate monomer, a crosslinker, and a photoinitiator. This composition exhibits high viscosity that resembles the viscosity of a workable two part system after the monomer liquid and the polymer have been mixed. This composition can be shaped to form nail coatings without any additional use of monomers liquid, followed by an exposure to UV light to photopolymerize the composition to create a hard, durable nail coating. Additional ingredients such as colorants and antioxidants may be included in the composition of the present invention. | 2017-12-21 |
20170360684 | COMPOSITION COMPRISING POLYMER PARTICLES, A HYDROCARBON-BASED OIL AND A SILICONE RESIN, AND PROCESS USING THE SAME - The present invention relates to a composition comprising particles of at least one polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being an isobornyl (meth)acrylate polymer chosen from isobornyl (meth)acrylate homopolymer and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate present in an isobornyl (meth)acrylate/C1-C4 alkyl (meth)acrylate weight ratio of greater than 4, at least one hydrocarbon-based oil and at least one silicone resin, and a mixture thereof. The invention also relates to a process for making up and/or caring for keratin materials, in which said composition is applied. | 2017-12-21 |
20170360685 | SKIN CARE COMPOSITIONS CONTAINING LIGHT DIFFUSER POLYMERIC BEADS - Disclosed are skin care compositions containing refractive polymeric particles. The composition improves the appearance of skin but reducing gloss without a noticeable presence on the skin surface. | 2017-12-21 |
20170360686 | PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC POLYMERS - Provided are compositions and methods that are useful for personal care compositions. The compositions comprise (a) a cationic polymer comprising polymerized units derived from (i) 30 to 80 weight % of cationic monomers, (ii) 10 to 65 weight % of (meth)acrylamide monomers, and (iii) 0 to 30 weight % of polar non-ionic derivatives of acrylic monomers, and (b) silicone. Also provided are methods of treating hair with such compositions. | 2017-12-21 |
20170360687 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF - The present invention concerns a substrate-based product comprising a water-insoluble substrate, at least one chemical exfoliator, and at least one skin binding agent, its method of preparation and its cosmetic uses. | 2017-12-21 |
20170360688 | PERSONAL CARE COMPOSITIONS CONTAINING COMPLEXING POLYELECTROLYTES - Compositions of the invention contain, in a cosmetically acceptable aqueous medium, a) a cationic polyelectrolyte, b) at least one surfactant; and (c) from about 0.01 to about 1.2 weight percent of an anionic polyelectrolyte, where the weight ratio of the anionic polyelectrolyte to the cationic polyelectrolyte is from about 0.05 to about 1.2, and where the composition exhibits a viscosity change that is below a minimum significant-change-threshold (Δηmin) and exhibits no measurable yield stress or increase in yield stress value when compared to a substantially identical composition that does not contain from about 0.01 to about 1.2 weight percent of the anionic polyelectrolyte, at a weight ratio of anionic polyelectrolyte to cationic polyelectrolyte of from about 0.05 to about 1.2. | 2017-12-21 |
20170360689 | DELIVERY OF HYDROPHOBIC BIOACTIVE AGENTS - A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as inflammation, and epidermal or musculoskeletal pain. | 2017-12-21 |
20170360690 | PITUITOUS SILICONE FLUID - A pituitous silicone fluid includes a hydrosilylation reaction product and a carrier fluid. The hydrosilylation reaction product is the reaction product of a first linear organopolysiloxane and a second linear organopolysiloxane. The first linear organo-polysiloxane includes (R | 2017-12-21 |
20170360691 | BIOACTIVE COMPOSITIONS HAVING HAIR ANTI AGING ACTIVITY - A bioactive composition and method of using the composition is provided having anti-aging, antioxidant and/or free radical scavenging properties. | 2017-12-21 |
20170360692 | USE OF AN EXTRACT OF LYTHRUM SALICARIA - The present invention relates to the cosmetic and/or nutraceutical use of an extract of the | 2017-12-21 |
20170360693 | CUSTOMIZED COSMETIC COMPOSITIONS, AND METHODS OF REJUVENATING AND UTILIZING CELLS AND/OR COMPONENTS THEREOF - Cosmetic formulations and compositions customized and/or personalized for rejuvenation of skin and/or hair are described. The cosmetic formulations are customized and/or personalized to include an extract and/or one or more molecular components in amounts and ratios naturally produced by rejuvenated cells or by cells modified toward rejuvenation. These cells are of skin and/or hair origin that have been reprogrammed, in which the skin and/or hair cells, having been rejuvenated and/or modified from the original cell, are initially obtained from a subject for which a customized cosmetic composition is for, or from a subject representative of a person for which a customized cosmetic composition is for. Reprogramming of the skin and/or hair cells provide rejuvenated cells, embryonic stem cell-like pluripotent cells, and/or transdifferentiated or differentiated young or younger cells that have been transdifferentiated from the rejuvenated or modified cells or differentiated from the embryonic stem cell-like pluripotent cells. Methods of selecting, preparing, and formulating the customized cosmetic products are also described. | 2017-12-21 |
20170360694 | COMPOSITION FOR IMPROVING THE CELLULITE APPEARANCE OF SKIN - The present invention relates to the use by oral route of a composition for oral administration comprising at least one probiotic and at least one B group vitamin, for improvement the cellulite appearance of skin. | 2017-12-21 |
20170360695 | UV-RESISTANT MICROBES AND UV-BLOCKING MICROBIAL EXTRACT - The present disclosure relates to a composition including an extract from an | 2017-12-21 |
20170360696 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided. | 2017-12-21 |
20170360697 | STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS - Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness. | 2017-12-21 |
20170360698 | Multi-Component Bolus - Disclosed is a bolus for oral administration to an animal, the bolus comprising at least one beneficial substance to be delivered to the animal, the bolus comprising two components which are adhered together by a water-soluble adhesive or sealant, such that the two components are separable in vivo, and wherein at least one of the aforesaid components is frangible in vivo, the frangible component being initially stabilised by the adherence thereto of the other of the aforesaid components, such that separation of the two components in vivo facilitates the breakage of the frangible component. | 2017-12-21 |
20170360699 | APPARATUS FOR COMPOUND DISPERSION - Methods and apparatuses for dispersing a compound within the patient are described. In one embodiment, an effective amount of a compound may be present in the cerebrospinal fluid of a patient and a force may be applied to the torso of the patient sufficient to enhance the convection of the cerebrospinal fluid. In another embodiment, a bolus including a compound may be injected into the cerebrospinal fluid of a patient. The volume of the bolus may be between about 5% and 30% of the total volume of the cerebrospinal fluid of the patient. | 2017-12-21 |
20170360700 | Flavored Non-Fructose Compositions and Methods for Negating Dehydration - Embodiments of the present invention are directed to ingredients, formulations, methods of manufacture and use of an oral rehydration solution (“ORS”) in the prevention and treatment of dehydration in humans. More specifically, invention embodiments relate to flavored electrolyte drink mixtures that relieve the dehydrating effects caused by travel, exercise, over-indulgence of toxic substances, and various illnesses in individual subjects. An ORS embodiment of the present invention restores fluid and electrolyte balance in humans as fast and as effectively as IV therapy, and thereby reduces the incidence of dehydration in human populations as well as rehydrating individuals in circumstances where IV therapy is not practical or wanted. The disclosed ORS therapies and packs may be used in conjunction with IV therapy as a multi-part strategy to allow hospitals to lower patient re-admission rates, lower staffing needs, give outpatient self-therapy to treatments prescribed outside of the hospital environment, and thus lower treatment and process costs while not reducing system or treatment efficacy. | 2017-12-21 |
20170360701 | DIETARY SUPPLEMENT FOR IMPROVING BRAIN HEALTH - Compositions that can be used to improve human health, and in particular brain health are provided. In some embodiments the composition comprises Inositol, N-Acetyl L-Tyrosine, pyrroloquinoline quinone (PQQ), Choline bitartrate, L-Theanine and Acetyl-L-Carnitine. The compositions may be administered to a subject, for example in the form of a liquid drink, to improve brain health. | 2017-12-21 |
20170360702 | Solid Solution Compositions and Use in Chronic Inflammation - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2017-12-21 |
20170360703 | AMPHIPHILIC POLYMER - The present application relates to an amphiphilic polymer and a method of preparing the same. | 2017-12-21 |
20170360704 | AMPHIPHILIC ENTITY NANOPARTICLES - The present invention provides nanoparticle compositions comprising AE nanoparticles. The present invention provides AE nanoparticles comprising one or more amphiphilic entities and pharmaceutical compositions comprising AE nanoparticles. The present invention provides methods of manufacturing AE nanoparticles. The present invention provides methods of delivering a biologically active agent to a subject by administering AE nanoparticles containing a biologically active agent to a subject. | 2017-12-21 |
20170360705 | FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF - The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof. | 2017-12-21 |
20170360706 | COMPOSITIONS AND METHODS FOR INDUCING NANOPARTICLE-MEDIATED MICROVASCULAR EMBOLIZATION OF TUMORS - Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM. Nitric oxide sequestration may cause a reduction in available extracellular nitric oxide in the tumor endothelium, which may prompt a widespread shutdown of vascular flow, hemorrhage, and necrosis. In particular, shutdown of vascular flow may trigger changes in nitric oxide production as well as trigger an acute inflammatory response, which may create reactive nitrogen species that are particularly destructive to the microvasculature. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors. | 2017-12-21 |
20170360707 | ANTICANCER COMPOSITIONS - The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and a poly(meth)acrylate copolymer. In one aspect, the solid dispersion of ARN-509 and a poly(meth)acrylate copolymer is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and a poly(meth)acrylate copolymer and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and a poly(meth)acrylate copolymer is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and a poly(meth)acrylate copolymer in a suitable solvent. | 2017-12-21 |
20170360708 | SOLID DISPERSION OF DECOQUINATE, A PREPARATION PROCESS AND ITS APPLICATION - The present invention relates to a hot melt extrusion composition, a process for preparing a hot melt extruded product using the hot melt extrusion composition, a solid dispersion of decoquinate, and pharmaceutical uses of the composition and the solid dispersion of decoquinate. The hot melt extrusion composition comprises 5 to 30% of decoquinate, 60 to 90% of a polymeric carrier and 0 to 10% of a surfactant. The hot melt extrusion composition can be melted into a liquid at a temperature below the melting point of decoquinate to achieve complete mixing, effectively avoiding the possible thermal decomposition of decoquinate and other components of the composition during the hot-melt process, thus retaining their original structures and pharmacodynamic activity. In the solid dispersion of decoquinate according to the present invention, the active pharmaceutical ingredient and the formulation excipients are melted into amorphous material with homogeneity, possessing improved solubility and drug releasing rate as well as enhanced oral bioavailability and efficacy. | 2017-12-21 |
20170360709 | CARRIER-FREE NANOPARTICLES - A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystalized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX). | 2017-12-21 |
20170360711 | FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING - The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm | 2017-12-21 |
20170360712 | Analysis Compensation Including Segmented Signals - A biosensor system determines analyte concentration from an output signal generated from a light-identifiable species or a redox reaction of the analyte. The biosensor system compensates at least 50% of the total error in the output signal with a primary function and may compensate a portion of the residual error with at least one residual function. An SSP function may serve as the primary function, first residual function, or second residual function. Preferably, when the SSP function serves as the first residual function, the SSP function compensates at least 50% of the residual error remaining after primary compensation. Preferably, when the SSP function serves as the second residual function, the SSP function compensates at least 50% of the residual error remaining after primary and first residual compensation. The error compensation provided by the primary, first residual, and second residual functions may be adjusted with function weighing coefficients. | 2017-12-21 |
20170360713 | ANTICANCER COMPOSITIONS - The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS in a suitable solvent. | 2017-12-21 |
20170360714 | Real-time Compounding 3D Printer - A method for delivery of personalized medication or nutrition for an individual is provided. The method includes receiving parameters for the personalized medication at a 3D printer, wherein the parameters comprise one or more ingredients, mixing at least one of the ingredients at the 3D printer, and micro-dispensing the one or more of the ingredients into dose form at the 3D printer. | 2017-12-21 |
20170360715 | MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS - The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w. | 2017-12-21 |
20170360716 | SEPARABLE CAPSULE - The present disclosure relates to a separable hard capsule for containing a medication. The capsule may be opened by finger force and used, for example, by pediatric and geriatric patients. | 2017-12-21 |
20170360717 | Nanowire-Coated Microdevice and Method of Making and Using the Same - A microdevice containing a plurality of nanowires on a biocompatible surface, and methods of making and using the same are provided. Aspects of the present disclosure include forming a plurality of microdevices on a substrate where each microdevice includes a plurality of nanowires. The nanowires may be loaded with an active agent by disposing the active agent onto the surface of the nanowires. Also provided herein are kits that include the subject microdevices. | 2017-12-21 |
20170360718 | INTRANASAL DENTAL ANESTHETIC - The present invention relates to intranasally administered pharmaceutical compositions administered for use in anesthesia. Such pharmaceutical compositions comprise benzyl alcohol. The invention also relates to methods for anesthetizing the maxillary dental arch using these pharmaceutical compositions. | 2017-12-21 |
20170360719 | NOVEL METHOD OF USE - The present invention relates to a novel method of treatment of acne in a human patient in need thereof, comprising administering topically to said patient an effective amount of the compound 3,5-Dihydroxy-4-isopropyl-trans-stilbene (Compound 1) or a pharmaceutically acceptable salt thereof. | 2017-12-21 |
20170360720 | METHOD TO SUPPLEMENT HUMAN IMMUNE SYSTEM IN SUPPRESSING HSV SYMPTOMS - Some embodiments of the invention relate to methods of administering orally a therapeutically effective pharmaceutical formulation of between about 3,000 micrograms to about 12,000 micrograms of allicin in a pharmaceutical dosage form to a patient with a herpes simplex viral infection, the therapeutically effective pharmaceutical formulation of allicin for increasing a human immune system activity in the patient during a reactivation of a herpes simplex virus causing a prodromal phase of the herpes simplex virus outbreak in the patient, the increasing of the human immune system activity in the patient for suppressing a herpes simplex viral symptom in the patient. In a preferred embodiment of the invention, an initial allicin dose of between about 7,200 micrograms to about 12,000 micrograms is administered once to an HSV patient and then at hourly or daily intervals, nine allicin doses additional of between about 3,000 micrograms to about 4800 micrograms are administered to the HSV patient. | 2017-12-21 |
20170360721 | HYDROXYNAPHTHOQUINONE COMPOUNDS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER - A compound suitable for treating EGFR-dependent non-small cell lung cancer exceptionally inhibits activity of the EGFR kinase, in particular in EGFR-dependent non-small cell lung cancer with intrinsic or acquired resistance against at least one EGFR inhibitor. Methods for inhibiting EGFR kinase activity in non-small cell lung cancer cells which harbor an abnormality in the EGFR gene and for targeting cancer cells harboring an abnormality in EGFR gene by contacting EGFR-dependent non-small cell lung cancer cells with said compound are also provided. The compounds allow for an advantageous inhibition of the EGFR kinase activity and induction of apoptosis of the non-small cell lung cancer cells with abnormality in the EGFR gene. Hence, said compounds represent a highly promising treatment option for patients harboring EGFR-dependent cancer. | 2017-12-21 |
20170360722 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC - 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione (DMDD), as well as variants, derivatives, analogs, modifications, and conjugates thereof, are identified as therapeutic agents for treating or preventing human cancers and precancerous conditions. DMDD can be isolated from the root of | 2017-12-21 |
20170360723 | USE OF RASAGILINE FOR THE TREATMENT OF RESTLESS LEGS SYNDROME - Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 2017-12-21 |
20170360724 | METHODS OF PREVENTING NEURODEGENERATION OF ASSOCIATION CORTEX IN A MAMMAL - The present invention provides methods of preventing and/or reducing risk of neurodegeneration of association cortex, and/or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need thereof. In certain embodiments, the method comprises administering to the mammal a therapeutically effective amount of an α | 2017-12-21 |
20170360725 | FKBP52-SPECIFIC ANDROGEN RECEPTOR INHIBITOR, MJC13, FOR USE IN TREATING BREAST CANCER - Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof. | 2017-12-21 |
20170360726 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described. | 2017-12-21 |
20170360727 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LACTATE METAL SALT - The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects. Therefore, the lactate metal salt can be widely utilized in a more effective anti-cancer therapy. | 2017-12-21 |
20170360728 | SYSTEMS AND METHODS FOR BIO-MATCHING GELS, CREAMS AND LOTIONS - A method of bio-matching a topical gel, cream or lotion includes selecting a vagina of a living body, identifying a secretion of the selected vagina, identifying a composition of the identified secretion, and formulating the topical gel to match the identified composition of the identified secretion. | 2017-12-21 |
20170360729 | TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 2017-12-21 |
20170360730 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD). | 2017-12-21 |
20170360731 | IMMUNOMODULATOR - An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient. | 2017-12-21 |
20170360732 | Methods and Drug Therapies for Patency of Occluded Blood Vessels Following Angioplasty - The present disclosure relates to a method of maintaining luminal patency of a blood vessel following vessel injury, the method including administering a composition comprising at least one lysyl oxidase inhibitor and D-penicillamine to a subject in need thereof Compositions to support the methods are also provided. | 2017-12-21 |
20170360733 | AGING INHIBITOR - An object of the present invention is to provide a senescence retarding agent that delays the onset of senescence symptoms and extends longevity, and is superior in safety. The senescence retarding agent of the present invention that achieves the object is characterized by containing a plant fermentation product as an active ingredient, the plant fermentation product being a mixture of the following: (a) a koji mold-fermented product of one or more kinds of beans and/or cereals selected from the group consisting of barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese millet, foxtail millet, and millet; (b) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of fruits selected from the group consisting of mikan (mandarin orange), grape, apple, yama-budo (crimson glory grape), peach, kaki (Japanese persimmon), | 2017-12-21 |
20170360734 | ANTI-RDS COMPOUNDS AND METHOD OF MANUFACTURE AND ADMINISTRATION THEREOF TO INDUCE DOPAMINE HOMEOSTATIS - Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis. These compounds synergistically combine two or more of (a) DP A, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostatis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In embodiments of the present invention, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DP A, NAC, and kyotorphin are not soluble in water. | 2017-12-21 |
20170360735 | INGESTIBLE EMULSION MATRIX FOR DELIVERY OF CREATINE - Disclosed are compositions for improved oral delivery of creatine, methods of making such compositions, and kits comprising such compositions. In particular, the compositions are capable of dispensing a high dose of creatine in a convenient manner that does not require the consumption of liquids. The creatine is encapsulated in an emulsion matrix delivery system that contains a very low moisture level to keep the creatine in solid state, thus unexposed to moisture or acidic conditions, thereby preserving the creatine from hydrolysis, dissociation or other undesirable conversion into creatinine. | 2017-12-21 |
20170360736 | Compositions And Methods For Treating Intestinal Hyperpermeability - The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor. | 2017-12-21 |
20170360737 | LONG-CHAIN POLYUNSATURATED FATTY-ACID-CONTAINING FAT AND FOOD CONTAINING SAME - The present invention addresses the problem of providing a versatile, flavorful long-chain polyunsaturated fatty-acid-containing fat having exceptional oxidation stability, and a food that utilizes the fat. The problem can be solved by a long-chain polyunsaturated fatty-acid-containing fat having a specific linoleic acid content and a specific tocopherol-tocotrienol content, the fat containing a fatty acid having five or more double bonds. | 2017-12-21 |
20170360738 | COMPOSITIONS CONTAINING AS THE ACTIVE INGREDIENT COMPONENTS FROM SALVIA SCLAREA SEED - The present invention concerns a food supplement comprising | 2017-12-21 |
20170360739 | COMPOSITIONS AND METHODS COMPRISING MEDIUM CHAIN TRIGLYCERIDES FOR TREATMENT OF EPILEPSY - The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal. | 2017-12-21 |
20170360740 | HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. | 2017-12-21 |
20170360741 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors - A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula | 2017-12-21 |